| Project/Area Number |
06454470
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
TOMODA Yutaka Nagoya University Professor, 医学部, 教授 (60023769)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAMAKOSHI Kouji Nagoya University, 医学部, 助手 (30262900)
KIKKAWA Fumitaka Nagoya University, 医学部, 講師 (40224985)
水野 公雄 名古屋大学, 医学部, 講師 (40252241)
|
|---|
| Project Period (FY) |
1994 – 1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥7,100,000 (Direct Cost: ¥7,100,000)
Fiscal Year 1996: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1995: ¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 1994: ¥3,600,000 (Direct Cost: ¥3,600,000)
|
|---|
| Keywords | Ovarian Tumor / Recurrence / MMP / Zymography |
|---|
| Research Abstract |
PVB regimen was superior to CAP regimen for ovarian cancer (p<0.05). Although difference of survival rate increased between 2 regimems within 24 months, thereafter survival rates decreased gradually at the same rate. Furthermore, there were no difference observed between 2 regimen in disease free survival. These results suggested that primary treatment including operation and chemotherapy was very important to improve survival for ovarian cancer. One hundred and fifty borderline malignancy cases were also analyzed. One hundred and twenty-five cases were stage I and 52 cases were managed conservely pregnancy potencial. Although stage I cases received no adjuvant therapy after operation, no cases died, suggesting that adjuvant therapy was meanless in stage I cases. On the other hand, 9 cases died among 25 with stage II or more. Thus, adjuvant chemotherapy including cisplatin might be performed in advanced cases. However, adjuvant chemotherapy would not be effective on mucinous borderline cases as well as mucinous cancer. MMPs and TIMPs have been focused for cancer cell invasion and metastasis. These proteins were examined in gynecologic cancer tissues by using gelatin zymography and reverse zymography. The secretion of MMPs increased more in cancer tissues than that in normal tissues and specially MMP-9 increased remarkably in cancer tissues, although this enzyme was secreted little in normal tissues. The secretion fo TIMP-1 increased more in cancer tissues than that in normal tissues. Furthermore, we examined these proteins in peritoneum, myometrium and ovary. MMP-9 was secreted mostly in peritoneum and TIMP-1 in ovary. Conditioned medium of these normal tissues had the potency to induce MMPs and TIMPs from ovarian cancer cells. These results suggested that the influence of normal tissues on cancer cells was strongly associated with cancer cells invasion.
|
